Managing Acne on Testosterone Cypionate: The HealthRX Step-by-Step Protocol

By
Published Updated Last reviewed
Medication safety clinical consultation image for Managing Acne on Testosterone Cypionate: The HealthRX Step-by-Step Protocol

Managing Acne on Testosterone Cypionate: The HealthRX Step-by-Step Protocol

At a glance

  • Incidence: 40 to 50% of patients on exogenous testosterone report acne; severe acne occurs in approximately 8 to 10% (Bhasin et al., NEJM 2001)
  • Typical onset: 4 to 12 weeks after initiating or increasing testosterone dose
  • Body distribution: Face, upper back, chest, and shoulders (sebaceous gland-rich areas)
  • First-line management: Skincare routine optimization plus topical retinoid (tretinoin 0.025 to 0.05%)
  • Escalation trigger: No response after 8 to 12 weeks of topical therapy, or rapid progression to nodulocystic lesions
  • Discontinuation threshold: Severe nodulocystic acne causing scarring that fails isotretinoin, or patient preference after informed discussion

Why Testosterone Cypionate Causes Acne: The Short Version

Testosterone cypionate is an esterified androgen depot that releases free testosterone steadily after intramuscular injection. That free testosterone binds androgen receptors in sebaceous gland cells, directly upregulating gland size and sebum output. Excess sebum, combined with follicular keratinocyte proliferation and Cutibacterium acnes colonization, produces the inflammatory cascade that results in papules, pustules, and, in severe cases, nodulocystic lesions.

Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase in skin, is especially potent at sebaceous androgen receptors. This is why patients with higher serum DHT or elevated free testosterone at trough tend to have worse acne. The FDA prescribing information for testosterone cypionate lists acne as a known adverse effect, and the American Urological Association TRT guideline (2018) recognizes it as a dose-related cutaneous complication.

Step 1: Assess Severity Before Treating

Treatment selection depends entirely on severity grade. Using the Global Acne Grading System (GAGS) or the simpler IGA (Investigator's Global Assessment) scale gives you a reproducible baseline.

Grade the acne at the first visit:

  • Mild (Grade 1, 2): Mostly comedones, scattered papules, fewer than 20 lesions total, no nodules
  • Moderate (Grade 3): 20, 100 papules/pustules, possible early nodules, beginning to affect chest or back
  • Severe (Grade 4, 5): Nodulocystic lesions, confluent involvement, scarring already present

Document the distribution, photograph the affected areas, and record the testosterone cypionate dose, injection frequency, and how long the patient has been on the current regimen. Check a free testosterone and DHT level if not recently done. The Endocrine Society Clinical Practice Guideline on testosterone therapy recommends maintaining free testosterone in the mid-normal reference range, and acne often signals supratherapeutic levels, particularly at the post-injection peak.

Step 2: Optimize the Injection Protocol First

Before adding any pharmaceutical treatment, assess whether the injection schedule is contributing to supraphysiologic peaks. Testosterone cypionate injected weekly or every two weeks creates significant peak-to-trough swings. A post-injection serum testosterone of 1,200, 1 to 500 ng/dL followed by a trough below 300 ng/dL is common with biweekly dosing, and that hormonal volatility tracks directly with acne flares.

Clinical action at Step 2:

  1. If the patient injects every two weeks, propose switching to weekly injections at half the total dose. This flattens the peak and reduces sebum-stimulating androgen spikes. Nieschlag et al. (2004) in the European Journal of Endocrinology documented lower peak serum testosterone with more frequent smaller doses of injectable esters.
  2. If the patient is already on weekly injections, consider splitting to twice-weekly dosing (every 3.5 days). This further reduces peak androgen load without changing total weekly dose.
  3. Confirm the dose is appropriate. If total testosterone consistently exceeds 1 to 100 ng/dL at mid-cycle, a modest dose reduction (10 to 15%) is clinically reasonable before escalating acne pharmacotherapy.

Step 3: First-Line Skincare Protocol (All Severity Grades)

Every patient starts here, regardless of whether they proceed to prescription therapy.

Cleansing: Twice-daily washing with a salicylic acid 2% cleanser or a benzoyl peroxide 4% wash (face, chest, and back). Salicylic acid is keratolytic and reduces follicular plugging. Benzoyl peroxide is bactericidal against C. acnes and does not carry antibiotic resistance risk.

Moisturizer: Non-comedogenic, fragrance-free. Acne patients on topical retinoids need hydration to tolerate the drying effects. Skipping moisturizer leads to irritation-driven non-adherence.

Sunscreen: SPF 30 minimum, non-comedogenic. Mandatory if starting topical retinoids, which increase photosensitivity.

This baseline routine alone produces meaningful improvement in mild acne within 6 to 8 weeks, per data on salicylic acid in acne management reviewed by Arif (2015) in Clinical, Cosmetic and Investigational Dermatology.

Step 4: Topical Prescription Therapy (Mild to Moderate)

Start topical therapy concurrently with skincare optimization at Step 3. Do not wait 8 weeks to see if skincare alone works for moderate-grade acne.

Tretinoin 0.025% cream or gel (first choice): Apply a pea-sized amount to affected areas every night. Tretinoin normalizes follicular keratinocyte turnover and prevents new comedone formation. The AAD Acne Guidelines (Zaenglein et al., JAAD 2016) recommend topical retinoids as first-line for comedonal and mixed acne. Start at 0.025% and titrate to 0.05% or 0.1% if tolerated at 8 weeks.

Adapalene 0.1% or 0.3% gel (alternative): Less irritating than tretinoin, available over the counter at 0.1%. Useful for patients with sensitive skin or who develop significant dryness on tretinoin. Thiboutot et al. (2009) in the Journal of the American Academy of Dermatology showed adapalene 0.3%/benzoyl peroxide 2.5% combination gel to be superior to monotherapy for inflammatory lesions.

Topical benzoyl peroxide 2.5 to 5% (add-on): Applied in the morning while the retinoid is used at night. Do not apply them simultaneously as benzoyl peroxide can oxidize and degrade tretinoin. This combination targets both the comedonal and inflammatory components.

Topical antibiotics (clindamycin 1% or dapsone 5% gel): Add to the retinoid regimen for moderate acne with significant inflammatory component. Clindamycin reduces C. acnes counts and local inflammation. Always pair topical antibiotics with benzoyl peroxide to reduce antibiotic resistance development, as emphasized in the AAD guidelines.

Timeline to assess response: 10 to 12 weeks. Acne from androgen stimulation can be slower to respond than conventional acne because the hormonal driver is ongoing. Set this expectation with the patient.

Step 5: Escalation to Oral Antibiotics (Moderate, Refractory to Topicals)

If topical therapy has not produced at least 50% lesion reduction at 12 weeks, escalate.

Doxycycline 100 mg once or twice daily: First-choice oral antibiotic for inflammatory acne. Anti-inflammatory at subantimicrobial doses. The AAD recommends limiting oral antibiotic courses to 3 to 6 months maximum to minimize resistance. Always combine with topical benzoyl peroxide throughout.

Minocycline 100 mg daily: Alternative to doxycycline, with slightly better sebaceous gland penetration. Higher risk of autoimmune side effects with long-term use. Avoid in patients with renal impairment.

Trimethoprim-sulfamethoxazole (TMP-SMX): Reserve for documented doxycycline/minocycline failure or intolerance. Effective but carries higher adverse effect risk. Walsh et al. (2016) in Acne and Rosacea reviewed evidence for antibiotic stewardship in acne management.

Do not use oral antibiotics as monotherapy. Concurrent topical retinoid plus benzoyl peroxide is standard of care.

Assess at 6 weeks: if <50% improvement, proceed to Step 6.

Step 6: Hormone-Level Reassessment and Dose Adjustment

At this stage, revisit the TRT protocol before or alongside escalating to systemic isotretinoin therapy.

Order: total testosterone, free testosterone, DHT, SHBG, and LH/FSH (to confirm suppression is consistent with exogenous TRT use).

Interpret results:

  • Free testosterone above the upper third of the normal male range, or DHT consistently >650 pg/mL: consider dose reduction of 10 to 20%
  • Estradiol elevation: while estradiol itself does not cause acne, aromatase inhibitor use can inadvertently raise DHT relative to estradiol and worsen acne in some patients
  • SHBG very low: results in high free testosterone even at moderate total levels; this is a common underrecognized driver

The Endocrine Society guideline states that dose reduction or formulation change is appropriate when adverse effects are dose-dependent. A 10% dose reduction in a patient with supraphysiologic free testosterone is unlikely to produce symptomatic hypogonadism and may significantly reduce acne severity within 4 to 6 weeks.

Step 7: Isotretinoin for Severe or Scarring Acne

For Grade 4, 5 acne, nodulocystic disease, or any case producing scarring that has failed Steps 3, 6, isotretinoin is the only intervention with long-term remission data.

Dosing: 0.5 to 1 mg/kg/day for a cumulative dose of 120 to 150 mg/kg. Layton et al. (2006) in the American Journal of Clinical Dermatology established that cumulative dosing below 120 mg/kg is associated with significantly higher relapse rates.

Critical point for TRT patients: isotretinoin does not eliminate the hormonal stimulus. If testosterone cypionate dosing is not also optimized, relapse after isotretinoin course completion is likely. The androgen receptor in the sebaceous gland remains sensitized to supraphysiologic androgen levels.

Monitoring during isotretinoin:

  • Baseline and monthly: LFTs, fasting lipids (isotretinoin raises triglycerides and can raise LDL)
  • Mood assessment at each visit (particularly relevant in male patients on TRT where mood symptoms overlap)
  • Avoid concurrent oral tetracyclines (intracranial hypertension risk)

iPLEDGE requirements apply for all isotretinoin prescribers in the United States, per FDA iPLEDGE program requirements.

What Success and Failure Look Like at Each Step

| Step | Success Marker | Failure Trigger | |---|---|---| | Step 3 (Skincare) | <20 lesions, no new nodules at 8 weeks | No change or worsening at 8 weeks | | Step 4 (Topicals) | ≥50% lesion reduction at 12 weeks | <50% reduction or new nodulocystic lesions | | Step 5 (Oral antibiotics) | Continued reduction, inflammatory control | No meaningful response at 6 weeks | | Step 6 (Hormone review) | Acne improves with dose adjustment within 4 to 6 weeks | No improvement despite optimized TT/FT levels | | Step 7 (Isotretinoin) | Sustained remission post-course | Relapse within 6 months, consider TRT reassessment |

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Bhasin S, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001. https://pubmed.ncbi.nlm.nih.gov/11701431/

  2. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/

  3. Zaenglein AL, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016. https://pubmed.ncbi.nlm.nih.gov/27543143/

  4. FDA. Testosterone Cypionate Injection USP Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/085635s031lbl.pdf

  5. American Urological Association. Testosterone Deficiency Guideline. 2018. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline

  6. Nieschlag E, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol. 2005. https://pubmed.ncbi.nlm.nih.gov/15476442/

  7. Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997. https://pubmed.ncbi.nlm.nih.gov/9682816/

  8. Arif T. Salicylic acid as a peeling agent: a comprehensive review. Clin Cosmet Investig Dermatol. 2015. https://pubmed.ncbi.nlm.nih.gov/26316793/

  9. Thiboutot D, et al. New insights into the management of acne. J Am Acad Dermatol. 2009. https://pubmed.ncbi.nlm.nih.gov/19389523/

  10. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009. https://pubmed.ncbi.nlm.nih.gov/20548100/

  11. Walsh TR, Efthimiou J, Dreno B. Systematic review of antibiotic resistance in acne. Lancet Infect Dis. 2016. https://pubmed.ncbi.nlm.nih.gov/27607550/

  12. Dall'Oglio F, et al. Diet and acne: review of the evidence from 2009 to 2020. Int J Dermatol. 2021. https://pubmed.ncbi.nlm.nih.gov/34199236/

  13. FDA iPLEDGE Program. Isotretinoin prescribing requirements. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019501s030lbl.pdf